NRx Pharmaceuticals Applies for FDA National Priority Voucher for Intravenous Ketamine (NRX-100)
Psychiatric Times
JUNE 23, 2025
SHOW MORE NRx Pharmaceuticals advances NRX-100, a preservative-free ketamine, through a fast-tracked FDA review for treating suicidal depression and PTSD. Sanom/Adobestock BREAKING NEWS A new formulation of ketamine is progressing through a novel US Food and Drug Administration review pathway, announced NRx Pharmaceuticals.
Let's personalize your content